Efficacy and safety of digital nerve block for pain management during sharp debridement of digital ulcers in systemic sclerosis: A prospective observational study
- PMID: 39544895
- PMCID: PMC11559528
- DOI: 10.1177/23971983241285206
Efficacy and safety of digital nerve block for pain management during sharp debridement of digital ulcers in systemic sclerosis: A prospective observational study
Abstract
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis and vascular abnormalities, often leading to the development of digital ulcers (DUs). DUs are painful and debilitating, significantly impacting patients' quality of life. Effective pain management during debridement is crucial, yet there is no consensus on the optimal approach. This study evaluates the efficacy and safety of digital nerve block (DNB) using lidocaine and mepivacaine for pain control during sharp debridement of DUs in SSc patients.
Methods: This prospective observational study was conducted from September 2023 to May 2024 at the Rheumatology Operating Unit, University of Verona. Patients were randomized to receive either 1 mL of 2% lidocaine or 2% mepivacaine for DNB. Pain levels were assessed using a categorical grading scale during the injection and debridement. The outcomes were pain control and performance of lidocaine versus mepivacaine.
Results: The cohort developed 46 ulcers. The pain was abolished in almost all patients. Lidocaine achieved faster anaesthesia (127.92 ± 34.32 s) compared with mepivacaine (252.65 ± 49.89 s, p < 0.001). Mepivacaine resulted in less pain during injection (p = 0.006). No significant difference in pain levels during debridement was observed between the two anaesthetics. Three mild adverse effects (Raynaud's phenomenon) were reported. All procedures were completed successfully, and 35 ulcers healed with a mean time of 6.1 ± 7.77 weeks.
Conclusions: DNB with mepivacaine provides effective pain control during DU debridement in SSc patients, with lower injection site pain and comparable efficacy to lidocaine. The procedure is safe, well-tolerated and facilitates successful ulcer healing. Further studies with larger cohorts are warranted to confirm these findings.
Keywords: Systemic sclerosis; anaesthetic; debridement; digital nerve block; digital ulcer.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Figures

Similar articles
-
Digital ulcer debridement in systemic sclerosis: a systematic literature review.Clin Rheumatol. 2020 Mar;39(3):805-811. doi: 10.1007/s10067-019-04924-4. Epub 2020 Jan 18. Clin Rheumatol. 2020. PMID: 31955323
-
Lidocaine controls pain and allows safe wound bed preparation and debridement of digital ulcers in systemic sclerosis: a retrospective study.Clin Rheumatol. 2017 Jan;36(1):209-212. doi: 10.1007/s10067-016-3414-7. Epub 2016 Sep 29. Clin Rheumatol. 2017. PMID: 27686661
-
The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort.Rheumatol Immunol Res. 2022 Jul 6;3(2):84-89. doi: 10.2478/rir-2022-0014. eCollection 2022 Jun. Rheumatol Immunol Res. 2022. PMID: 36465326 Free PMC article.
-
Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.J Dermatol. 2016 Jan;43(1):56-62. doi: 10.1111/1346-8138.13030. Epub 2015 Jul 15. J Dermatol. 2016. PMID: 26173902
-
A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review.JAMA Dermatol. 2021 Jul 1;157(7):851-858. doi: 10.1001/jamadermatol.2021.1463. JAMA Dermatol. 2021. PMID: 34037677 Review.
Cited by
-
Pharmacological management of pain in digital ulcers of systemic sclerosis: A PRISMA-driven systematic review.J Scleroderma Relat Disord. 2025 Jul 24:23971983251352340. doi: 10.1177/23971983251352340. Online ahead of print. J Scleroderma Relat Disord. 2025. PMID: 40727417 Free PMC article. Review.
References
-
- Hughes M, Herrick AL. Digital ulcers in systemic sclerosis. Rheumatology 2017; 56(1): 14–25. - PubMed
-
- Wirz EG, Jaeger VK, Allanore Y, et al. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 2016; 75(7): 1285–1292. - PubMed
-
- Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud phenomenon. Medicine (Baltimore) 1980; 59(6): 393–408. - PubMed
-
- Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J Rheumatol 2007; 34(12): 2423–2430. - PubMed
-
- Tiev KP, Diot E, Clerson P, et al. Clinical features of scleroderma patients with or without prior or current ischemic digital ulcers: post-hoc analysis of a nationwide multicenter cohort (ItinérAIR-Sclérodermie). J Rheumatol 2009; 36(7): 1470–1476. - PubMed
LinkOut - more resources
Full Text Sources